Pulmonary hypertension historical perspective: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) (Created page with "__NOTOC__ {{Pulmonary hypertension}} {{CMG}}: {{AE}} {{AG}} ==Overview== ==Historical Perspective== PH was first classified into primary and secondary in 1973 during the World...") |
No edit summary |
||
| (10 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pulmonary hypertension}} | {{Pulmonary hypertension}} | ||
{{CMG}}: {{AE}} {{ | {{CMG}}: {{AE}} {{Jose}} | ||
==Overview== | ==Overview== | ||
[[Pulmonary hypertension]] was first described by [[Ernst von Romberg]], a German physician, in 1891. | |||
==Historical Perspective== | ==Historical Perspective== | ||
*[[Pulmonary hypertension]] was first described by [[Ernst von Romberg]], a German physician, in 1891. | |||
* In 1929, Werner Forssman demonstrated that it was possible to perform [[Right heart catheterization|right-sided catheterization]] in humans by performing [[catheterization]] on himself. | |||
* In 1951, Dresdale coined the term primary pulmonary hypertension after describing series of cases of this new pathology. He also investigated the effects of [[tolzoline]] in a woman with [[pulmonary arterial hypertension]] causing a sudden reduction in pulmonary vascular resistance. | |||
*In the late 1960s, there was an epidemic of [[pulmonary arterial hypertension]] induced by aminorex, which sparked interest in the disease. | |||
*[[Pulmonary hypertension]] was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland. | |||
*[[Bosentan]] was approved to treat [[pulmonary hypertension]] in 2001, and [[sildenafil]] was approved in 2005.<ref name="pmid19561874">{{cite journal| author=Barst RJ| title=Pulmonary hypertension: past, present and future. | journal=Ann Thorac Med | year= 2008 | volume= 3 | issue= 1 | pages= 1-4 | pmid=19561874 | doi=10.4103/1817-1737.37832 | pmc=2700428 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19561874 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Up-To-Date]] | |||
Latest revision as of 14:01, 9 June 2021
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension historical perspective On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension historical perspective |
|
Risk calculators and risk factors for Pulmonary hypertension historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]: Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
Overview
Pulmonary hypertension was first described by Ernst von Romberg, a German physician, in 1891.
Historical Perspective
- Pulmonary hypertension was first described by Ernst von Romberg, a German physician, in 1891.
- In 1929, Werner Forssman demonstrated that it was possible to perform right-sided catheterization in humans by performing catheterization on himself.
- In 1951, Dresdale coined the term primary pulmonary hypertension after describing series of cases of this new pathology. He also investigated the effects of tolzoline in a woman with pulmonary arterial hypertension causing a sudden reduction in pulmonary vascular resistance.
- In the late 1960s, there was an epidemic of pulmonary arterial hypertension induced by aminorex, which sparked interest in the disease.
- Pulmonary hypertension was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland.
- Bosentan was approved to treat pulmonary hypertension in 2001, and sildenafil was approved in 2005.[1]
References
- ↑ Barst RJ (2008). "Pulmonary hypertension: past, present and future". Ann Thorac Med. 3 (1): 1–4. doi:10.4103/1817-1737.37832. PMC 2700428. PMID 19561874.